Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy

Ophthalmic Epidemiology

Volumn 23, Issue 4, 2016, Pages 209-222

  Sabanayagam, Charumathi ^a,b,c   Yip, WanFen ^a   Ting, Daniel S W ^a   Tan, Gavin ^a   Wong, Tien Y ^a,b,c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Awareness; burden; diabetic retinopathy; prevention; risk factors

Indexed keywords

CANDESARTAN; LISINOPRIL;

AWARENESS; BLINDNESS; BLOOD PRESSURE; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; VISUAL IMPAIRMENT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; MACULAR EDEMA; MALE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INCIDENCE; MACULAR EDEMA; MALE; PREVALENCE; RISK FACTORS;

EID: 84976370547     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286586.2016.1193618     Document Type: Review

References (135)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137–149.
2. P.I.Burgess, I.J.MacCormick, S.P.Harding, et al. Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review. Diabet Med 2013;30:399–412.
3. C.S.Cockram The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 2000;6:43–52.
4. R.Khandekar Screening and public health strategies for diabetic retinopathy in the Eastern Mediterranean region. Middle East Afr J Ophthalmol 2012;19:178–184.
5. R.Klein, B.E.Klein Are individuals with diabetes seeing better? A long-term epidemiological perspective. Diabetes 2010;59:1853–1860.
6. R.Lee, T.Y.Wong, C.Sabanayagam Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015;2:17.
7. World Health Organization. Global initiative for the elimination of avoidable blindness Action Plan 2006–2011. Vision 2020, Report 2007.
8. J.W.Yau, S.L.Rogers, R.Kawasaki, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–564.
9. The Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial, 1995;102:647–661.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.
13. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981;88:583–600.
14. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995;113:1144–1155.
15. P.Mitchell, T.Y.Wong Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505–513.
16. L.Shi, H.Wu, J.Dong, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol 2015;99:823–831.
17. E.Kirkizlar, N.Serban, J.A.Sisson, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology 2013;120:2604–2610.
18. S.Jones, R.T.Edwards Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010;27:249–256.
19. S.L.Mansberger, C.Sheppler, G.Barker et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: a randomized clinical trial. JAMA Ophthalmol 2015;133:518–525.
20. G.Virgili, F.Menchini, G.Casazza, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2015;1:CD008081.
21. M.Adhi, J.S.Duker Optical coherence tomography – current and future applications. Curr Opin Ophthalmol 2013;24:213–221.
22. I.E.Zimmer-Galler, A.E.Kimura, S.Gupta Diabetic retinopathy screening and the use of telemedicine. Curr Opin Ophthalmol 2015;26:167–172.
23. D.S.Boyer, J.J.Hopkins, J.Sorof, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151–169.
24. A.Agarwal, R.Afridi, M.Hassan, et al. Novel therapies in development for diabetic macular edema. Curr Diab Rep 2015;15:75.
25. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414–1431.
26. World Health Organization. Diabetes Programme.Geneva: WHO, 2015.
27. International Diabetes Federation. IDF Diabetes atlas, 7th ed. Brussels, Belgium: Author, 2015. Accessed December20, 2015 from: http://www diabetesatlas org
28. Foundation ID. IDF Diabetes atlas, 6th ed. 2014. Accessed December22, 2015 from: https://www idf org/sites/default/files/Atlas-poster-2014_EN pdf [serial online]
29. J.E.Shaw, R.A.Sicree, P.Z.Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14.
30. S.Wild, G.Roglic, A.Green, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053.
31. H.Stovring, M.Andersen, H.Beck-Nielsen, et al. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003;362:537–538.
32. N.Cheung, P.Mitchell, T.Y.Wong Diabetic retinopathy. Lancet 2010;376:124–136.
33. M.Nordwall, M.Bojestig, H.J.Arnqvist, et al. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes – The Linkoping Diabetes Complications Study. Diabetologia 2004;47:1266–1272.
34. P.Hovind, L.Tarnow, K.Rossing, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258–1264.
35. G.Pambianco, T.Costacou, D.Ellis, et al. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006;55:1463–1469.
36. S.Cugati, A.Kifley, P.Mitchell, et al. Temporal trends in the age-specific prevalence of diabetes and diabetic retinopathy in older persons: population-based survey findings. Diabetes Res Clin Pract 2006;74:301–308.
37. T.Y.Wong, M.Mwamburi, R.Klein, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307–2313.
38. C.S.Arun, N.Ngugi, L.Lovelock, et al. Effectiveness of screening in preventing blindness due to diabetic retinopathy. Diabet Med 2003;20:186–190.
39. F.B.Hu Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249–1257.
40. M.M.Ibrahim, A.Damasceno Hypertension in developing countries. Lancet 2012;380:611–619.
41. R.Klein, M.D.Knudtson, K.E.Lee, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859–1868.
42. K.S.Reddy, S.Yusuf Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596–601.
43. X.Zhang, J.B.Saaddine, C.F.Chou, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA 2010;304:649–656.
44. R.Varma, F.Choudhury, R.Klein, et al. Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010;149:752–761.
45. D.C.Minassian, D.R.Owens, A.Reidy Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol 2012;96:345–349.
46. R.Klein, B.E.Klein, S.E.Moss, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16.
47. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 2012;12:346–354.
48. R.Klein, M.D.Knudtson, K.E.Lee, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497–503.
49. R.Klein, B.E.Klein, S.E.Moss, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801–1815.
50. P.Romero-Aroca, M.Baget-Bernaldiz, J.Fernandez-Ballart, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract 2011;94:126–132.
51. E.Martin-Merino, J.Fortuny, E.Rivero-Ferrer, et al. Incidence of retinal complications in a cohort of newly diagnosed diabetic patients. PLoS One 2014;9:e100283.
52. M.C.Leske, S.Y.Wu, A.Hennis, et al. Nine-year incidence of diabetic retinopathy in the Barbados Eye Studies. Arch Ophthalmol 2006;124:250–255.
53. N.Younis, D.M.Broadbent, S.P.Harding, et al. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabetic Med 2003;20:758–765.
54. N.Younis, D.M.Broadbent, J.P.Vora, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195–200.
55. C.D.Jones, R.H.Greenwood, A.Misra, et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care 2012;35:592–596.
56. R.L.Thomas, F.Dunstan, S.D.Luzio, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012;344:e874.
57. D.M.Gibson Diabetic retinopathy and age-related macular degeneration in the U.S. Am J Prev Med 2012;43:48–54.
58. N.M.Bressler, R.Varma, Q.V.Doan, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol 2014;132:168–173.
59. H.Funatsu, S.Hori, E.Shimizu, et al. Questionnaire survey on periodic ocular examination in Japanese diabetic patients. Am J Ophthalmol 2003;136:955–957.
60. O.S.Huang, W.T.Tay, P.G.Ong, et al. Prevalence and determinants of undiagnosed diabetic retinopathy and vision-threatening retinopathy in a multiethnic Asian cohort: the Singapore Epidemiology of Eye Diseases (SEED) study. Br J Ophthalmol 2015;99:1614–1621.
61. R.Dandona, L.Dandona, R.K.John, et al. Awareness of eye diseases in an urban population in southern India. Bull World Health Organ 2001;79:96–102.
62. R.Thapa, G.Paudyal, N.Maharjan, et al. Awareness of diabetic retinopathy among diabetic patients in Nepal. Acta Ophthalmol 2012;90:e242.
63. K.G.Abueleinen, H.El-Mekawey, Y.S.Saif, et al. Sociodemographic factors responsible for blindness in diabetic Egyptian patients. Clin Ophthalmol 2011;5:1593–1598.
64. S.Wang, G.Tikellis, N.Wong, et al. Lack of knowledge of glycosylated hemoglobin in patients with diabetic retinopathy. Diabetes Res Clin Pract 2008;81:e15–e17.
65. I.Tajunisah, P.Wong, L.Tan, et al. Awareness of eye complications and prevalence of retinopathy in the first visit to eye clinic among type 2 diabetic patients. Int J Ophthalmol 2011;4:519–524.
66. O.S.Huang, W.T.Tay, E.S.Tai, et al. Lack of awareness amongst community patients with diabetes and diabetic retinopathy: the Singapore Malay eye study. Ann Acad Med Singapore 2009;38:1048–1055.
67. F.M.Islam, R.Chakrabarti, S.Z.Islam, et al. Factors associated with awareness, attitudes and practices regarding common eye diseases in the general population in a rural district in Bangladesh: The Bangladesh Population-based Diabetes and Eye Study (BPDES). PLoS One 2015;10:e0133043.
68. P.Jin, J.Peng, H.Zou, et al. The 5-year onset and regression of diabetic retinopathy in Chinese type 2 diabetes patients. PLoS One 2014;9:e113359.
69. V.H.Tam, E.P.Lam, B.C.Chu, et al. Incidence and progression of diabetic retinopathy in Hong Kong Chinese with type 2 diabetes mellitus. J Diabetes Complications 2009;23:185–193.
70. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
71. D.ControlDiabetes and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647–661.
72. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968–983.
73. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389.
74. P.H.Wang, J.Lau, T.C.Chalmers Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306–1309.
75. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874–886.
76. M.Egger, S.G.Davey, C.Stettler, et al. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997;14:919–928.
77. Y.J.Cheng, E.W.Gregg, L.S.Geiss, et al. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care 2009;32:2027–2032.
78. P.P.Chiang, E.L.Lamoureux, C.Y.Cheung, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Invest Ophthalmol Vis Sci 2011;52:7586–7592.
79. G.K.Dowse, A.R.Humphrey, V.R.Collins, et al. Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. Am J Epidemiol 1998;147:448–457.
80. R.Pradeepa, R.M.Anjana, R.Unnikrishnan, et al. Risk factors for microvascular complications of diabetes among South Indian subjects with type 2 diabetes – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study-5. Diabetes Technol Ther 2010;12:755–761.
81. T.Y.Wong, N.Cheung, W.T.Tay, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008;115:1869–1875.
82. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
83. Y.Ohkubo, H.Kishikawa, E.Araki, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117.
84. M.Shichiri, H.Kishikawa, Y.Ohkubo, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl. 2):B21–B29.
85. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559.
86. F.Ismail-Beigi, T.Craven, M.A.Banerji, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419–430.
87. Group AC, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572.
88. B.Hemmingsen, S.S.Lund, C.Gluud, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898.
89. W.Duckworth, C.Abraira, T.Moritz, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139.
90. M.I.Harris, R.Klein, C.C.Cowie, et al. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care 1998;21:1230–1235.
91. R.Klein, S.E.Moss, B.E.Klein, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501–1510.
92. R.Klein, B.E.Klein, S.E.Moss, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989;149:2427–2432.
93. I.M.Stratton, E.M.Kohner, S.J.Aldington, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–163.
94. S.M.Tudor, R.F.Hamman, A.Baron, et al. Incidence and progression of diabetic retinopathy in Hispanics and non-Hispanic whites with type 2 diabetes. San Luis Valley Diabetes Study, Colorado. Diabetes Care 1998;21:53–61.
95. H.A.van Leiden, J.M.Dekker, A.C.Moll, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002;25:1320–1325.
96. D.R.Matthews, I.M.Stratton, S.J.Aldington, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122:1631–1640.
97. U.K.Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.
98. R.O.Estacio, B.W.Jeffers, N.Gifford, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(Suppl. 2):B54–B64.
99. N.Chaturvedi, A.K.Sjolie, J.M.Stephenson, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28–31.
100. N.Chaturvedi, M.Porta, R.Klein, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394–1402.
101. A.K.Sjolie, R.Klein, M.Porta, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385–1393.
102. M.Mauer, B.Zinman, R.Gardiner, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40–51.
103. J.W.Beulens, A.Patel, J.R.Vingerling, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009;52:2027–2036.
104. T.J.Lyons, A.J.Jenkins, D.Zheng, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004;45:910–918.
105. M.Rema, B.K.Srivastava, B.Anitha, et al. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study – 2. Diabet Med 2006;23:1029–1036.
106. M.A.Salinero-Fort, F.J.San Andres-Rebollo, C.de Burgos-Lunar, et al. Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study. PLoS One 2013;8:e76417.
107. T.Y.Wong, R.Klein, F.M.Islam, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006;141:446–455.
108. C.L.Morgan, D.R.Owens, P.Aubonnet, et al. Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study. BMJ Open 2013;3:e004025.
109. A.Keech, R.J.Simes, P.Barter, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–1861.
110. Group AS, Group AES, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233–244.
111. B.Staels, J.Dallongeville, J.Auwerx, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–2093.
112. R.Bordet, T.Ouk, O.Petrault, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34:1341–1346.
113. J.Kim, J.H.Ahn, J.H.Kim, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84:886–893.
114. S.Miranda, A.Gonzalez-Rodriguez, M.Garcia-Ramirez, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 2012;227:2352–2362.
115. M.Villarroel, M.Garcia-Ramirez, L.Corraliza, et al. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011;54:1543–1553.
116. T.Y.Wong, R.Simo, P.Mitchell Fenofibrate – a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 2012;154:6–12.
117. D.R.Owens, R.L.Gibbins, E.Kohner, et al. Diabetic retinopathy screening. Diabet Med 2000;17:493–494.
118. L.B.Backlund, P.V.Algvere, U.Rosenqvist New blindness in diabetes reduced by more than one-third in Stockholm County. Diabet Med 1997;14:732–740.
119. A.D.AssociationAmerican Diabetes. Executive summary: Standards of medical care in diabetes –2014. Diabetes Care 2014; 37(Suppl1.):S5–13.
120. N.K.Harris, N.Talwar, T.W.Gardner, et al. Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013;36:1562–1568.
121. R.J.Fante, T.W.Gardner, J.M.Sundstrom Current and future management of diabetic retinopathy: a personalized evidence-based approach. Diabetes Manag (Lond) 2013;3:481–494.
122. N.K.Harris, N.Talwar, T.W.Gardner, et al. Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013;36:1562–1568.
123. P.Gaede, P.Vedel, N.Larsen, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–393.
124. A.Sandbaek, S.J.Griffin, S.J.Sharp, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care 2014;37:2015–2023.
125. M.Rema, S.Premkumar, B.Anitha, et al. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci 2005;46:2328–2333.
126. L.Liu, X.Wu, L.Liu et al. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. PLoS One 2012;7:e45264.
127. P.K.Rani, R.Raman, A.Chandrakantan, et al. Risk factors for diabetic retinopathy in self-reported rural population with diabetes. J Postgrad Med 2009;55:92–96.
128. F.H.Wang, Y.B.Liang, F.Zhang, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology 2009;116:461–467.
129. World Health Organization, International Diabetes Federation. Diabetes action now. 2004. Accessed December15, 2015 from: http://www. who int/diabetes/actionnow/booklet/en/
130. World Health Organization. Prevention of blindness from diabetes mellitus. Report of a WHO Consultation in Geneva 2006.
131. M.O.Tso Changing scenery of eye care in China: from cataract to diabetic retinopathy. Arch Ophthalmol 2012;130:243–245.
132. World Health Organization. Universal Eye Health: A global action plan 2014–2019. Prevention of blindness and visual impairment 2013.
133. R.Khandekar Screening and public health strategies for diabetic retinopathy in the eastern Mediterranean region. Middle East Afr J Ophthalmol 2012;19:178–187.
134. Manperumalsamy. Guidelines for the comprehensive management of diabetic retinopathy in India. Aravind Eye Care System, Madurai, India: A VISION 2020 The Right to Sight India Publication, 2008.
135. F.B.von-Bischhoffshausen, C.FMCastro, P.Gomez-Bastar Planning diabetic retinopathy services – lessons from Latin America. Community Eye Health 2011;24:14–16.